Carboplatin-paclitaxel versus cisplatin-ifosfamide in the treatment of uterine carcinosarcoma a retrospective cohort study

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: Uterine carcinosarcoma (CS) is a rare neoplasm whose adjuvant treatment has not been yet defined. We report on the activity and toxicity of cisplatin-ifosfamide and carboplatin-paclitaxel as adjuvant treatments for patients with uterine CS. Methods: Data of International Federation of Gynecology and Obstetrics (FIGO) stage I to IVuterine CS patients treated between 2006 and 2012 with adjuvant chemotherapy (cisplatin 20 mg/mq and ifosfamide 1500 mg/mq day 1 to 4 every 3 weeks plus prophylactic Granulocyte colony-stimulating factor (G-CSF) support [group A] or carboplatin area under the curve-5 (AUC-5) and paclitaxel 175 mg/mq d1q21 [group B]) were retrospectively reviewed. Progression-free survival, overall survival, and chemotherapy-related toxicities were compared between the 2 groups. A subanalysis of oncologic outcomes according to the sarcomatous component (homologous vs heterologous) was performed. Results: Forty-six women were evaluated-21 in group A and 25 in group B. At a median follow-up of 30 months, the median progression-free survival was 11.6 months (95% confidence interval [CI], 6.3-16.9) and 16.6 months (95% CI, 14.7-18.5) for group A and B, respectively (P = 0.20). The median overall survival was 17.1 months (95% CI, 12.6-21.5) and 35.1 months (95% CI, 26.3-43.7) for group A and B, respectively (P = 0.14). No differences were identified among heterologous or homologous components according to chemotherapy treatment. Toxicity profiles widely differ between treatment arms. Conclusions: Because of the super imposable activity and the better toxicity profile, carboplatin-paclitaxel may be a suitable alternative to cisplatin-ifosfamide in the treatment of uterine CS.

Original languageEnglish
Pages (from-to)1256-1261
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume24
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Carcinosarcoma
Ifosfamide
Carboplatin
Cohort Studies
Retrospective Studies
Paclitaxel
Confidence Intervals
Cisplatin
Disease-Free Survival
Therapeutics
Drug Therapy
Survival
Self-Help Groups
Granulocyte Colony-Stimulating Factor
Adjuvant Chemotherapy
Gynecology
Obstetrics
Area Under Curve
TP protocol
Neoplasms

Keywords

  • Carboplatin
  • Carcinosarcoma
  • Chemotherapy
  • Paclitaxel
  • Uterine malignant mixed mullerian tumor

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

@article{87161e940b664fdc868edbd723e9ca68,
title = "Carboplatin-paclitaxel versus cisplatin-ifosfamide in the treatment of uterine carcinosarcoma a retrospective cohort study",
abstract = "Objective: Uterine carcinosarcoma (CS) is a rare neoplasm whose adjuvant treatment has not been yet defined. We report on the activity and toxicity of cisplatin-ifosfamide and carboplatin-paclitaxel as adjuvant treatments for patients with uterine CS. Methods: Data of International Federation of Gynecology and Obstetrics (FIGO) stage I to IVuterine CS patients treated between 2006 and 2012 with adjuvant chemotherapy (cisplatin 20 mg/mq and ifosfamide 1500 mg/mq day 1 to 4 every 3 weeks plus prophylactic Granulocyte colony-stimulating factor (G-CSF) support [group A] or carboplatin area under the curve-5 (AUC-5) and paclitaxel 175 mg/mq d1q21 [group B]) were retrospectively reviewed. Progression-free survival, overall survival, and chemotherapy-related toxicities were compared between the 2 groups. A subanalysis of oncologic outcomes according to the sarcomatous component (homologous vs heterologous) was performed. Results: Forty-six women were evaluated-21 in group A and 25 in group B. At a median follow-up of 30 months, the median progression-free survival was 11.6 months (95{\%} confidence interval [CI], 6.3-16.9) and 16.6 months (95{\%} CI, 14.7-18.5) for group A and B, respectively (P = 0.20). The median overall survival was 17.1 months (95{\%} CI, 12.6-21.5) and 35.1 months (95{\%} CI, 26.3-43.7) for group A and B, respectively (P = 0.14). No differences were identified among heterologous or homologous components according to chemotherapy treatment. Toxicity profiles widely differ between treatment arms. Conclusions: Because of the super imposable activity and the better toxicity profile, carboplatin-paclitaxel may be a suitable alternative to cisplatin-ifosfamide in the treatment of uterine CS.",
keywords = "Carboplatin, Carcinosarcoma, Chemotherapy, Paclitaxel, Uterine malignant mixed mullerian tumor",
author = "Domenica Lorusso and Fabio Martinelli and Maria Mancini and Italo Sarno and Antonino Ditto and Francesco Raspagliesi",
year = "2014",
doi = "10.1097/IGC.0000000000000215",
language = "English",
volume = "24",
pages = "1256--1261",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Carboplatin-paclitaxel versus cisplatin-ifosfamide in the treatment of uterine carcinosarcoma a retrospective cohort study

AU - Lorusso, Domenica

AU - Martinelli, Fabio

AU - Mancini, Maria

AU - Sarno, Italo

AU - Ditto, Antonino

AU - Raspagliesi, Francesco

PY - 2014

Y1 - 2014

N2 - Objective: Uterine carcinosarcoma (CS) is a rare neoplasm whose adjuvant treatment has not been yet defined. We report on the activity and toxicity of cisplatin-ifosfamide and carboplatin-paclitaxel as adjuvant treatments for patients with uterine CS. Methods: Data of International Federation of Gynecology and Obstetrics (FIGO) stage I to IVuterine CS patients treated between 2006 and 2012 with adjuvant chemotherapy (cisplatin 20 mg/mq and ifosfamide 1500 mg/mq day 1 to 4 every 3 weeks plus prophylactic Granulocyte colony-stimulating factor (G-CSF) support [group A] or carboplatin area under the curve-5 (AUC-5) and paclitaxel 175 mg/mq d1q21 [group B]) were retrospectively reviewed. Progression-free survival, overall survival, and chemotherapy-related toxicities were compared between the 2 groups. A subanalysis of oncologic outcomes according to the sarcomatous component (homologous vs heterologous) was performed. Results: Forty-six women were evaluated-21 in group A and 25 in group B. At a median follow-up of 30 months, the median progression-free survival was 11.6 months (95% confidence interval [CI], 6.3-16.9) and 16.6 months (95% CI, 14.7-18.5) for group A and B, respectively (P = 0.20). The median overall survival was 17.1 months (95% CI, 12.6-21.5) and 35.1 months (95% CI, 26.3-43.7) for group A and B, respectively (P = 0.14). No differences were identified among heterologous or homologous components according to chemotherapy treatment. Toxicity profiles widely differ between treatment arms. Conclusions: Because of the super imposable activity and the better toxicity profile, carboplatin-paclitaxel may be a suitable alternative to cisplatin-ifosfamide in the treatment of uterine CS.

AB - Objective: Uterine carcinosarcoma (CS) is a rare neoplasm whose adjuvant treatment has not been yet defined. We report on the activity and toxicity of cisplatin-ifosfamide and carboplatin-paclitaxel as adjuvant treatments for patients with uterine CS. Methods: Data of International Federation of Gynecology and Obstetrics (FIGO) stage I to IVuterine CS patients treated between 2006 and 2012 with adjuvant chemotherapy (cisplatin 20 mg/mq and ifosfamide 1500 mg/mq day 1 to 4 every 3 weeks plus prophylactic Granulocyte colony-stimulating factor (G-CSF) support [group A] or carboplatin area under the curve-5 (AUC-5) and paclitaxel 175 mg/mq d1q21 [group B]) were retrospectively reviewed. Progression-free survival, overall survival, and chemotherapy-related toxicities were compared between the 2 groups. A subanalysis of oncologic outcomes according to the sarcomatous component (homologous vs heterologous) was performed. Results: Forty-six women were evaluated-21 in group A and 25 in group B. At a median follow-up of 30 months, the median progression-free survival was 11.6 months (95% confidence interval [CI], 6.3-16.9) and 16.6 months (95% CI, 14.7-18.5) for group A and B, respectively (P = 0.20). The median overall survival was 17.1 months (95% CI, 12.6-21.5) and 35.1 months (95% CI, 26.3-43.7) for group A and B, respectively (P = 0.14). No differences were identified among heterologous or homologous components according to chemotherapy treatment. Toxicity profiles widely differ between treatment arms. Conclusions: Because of the super imposable activity and the better toxicity profile, carboplatin-paclitaxel may be a suitable alternative to cisplatin-ifosfamide in the treatment of uterine CS.

KW - Carboplatin

KW - Carcinosarcoma

KW - Chemotherapy

KW - Paclitaxel

KW - Uterine malignant mixed mullerian tumor

UR - http://www.scopus.com/inward/record.url?scp=84906858611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906858611&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000000215

DO - 10.1097/IGC.0000000000000215

M3 - Article

VL - 24

SP - 1256

EP - 1261

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 7

ER -